palmitoylcarnitine and Angiogenesis, Pathologic

palmitoylcarnitine has been researched along with Angiogenesis, Pathologic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Fu, Y; Patel, K; Rathod, D	1

Other Studies

1 other study(ies) available for palmitoylcarnitine and Angiogenesis, Pathologic

Article	Year
Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma. Experimental cell research, 2020, 11-01, Volume: 396, Issue:1 Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liposomes; Melanocytes; Models, Biological; Mutation; Nanocapsules; Neovascularization, Pathologic; Palmitoylcarnitine; Polyethylene Glycols; Protein Kinase C; Proto-Oncogene Proteins B-raf; Signal Transduction; Static Electricity; Transcription Factors; Vemurafenib	2020

Article

Year

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Experimental cell research, 2020, 11-01, Volume: 396, Issue:1

Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liposomes; Melanocytes; Models, Biological; Mutation; Nanocapsules; Neovascularization, Pathologic; Palmitoylcarnitine; Polyethylene Glycols; Protein Kinase C; Proto-Oncogene Proteins B-raf; Signal Transduction; Static Electricity; Transcription Factors; Vemurafenib

2020